NAYA Biosciences
NAYA Biosciences announced a strategic decision to separate its fertility and oncology businesses into distinct operations. The website includes an accessibility policy referencing WCAG 2.1 Level A and AA guidelines and provides contact information for accessibility inquiries.
Industries
Nr. of Employees
small (1-50)
NAYA Biosciences
NAYA Biosciences, Inc., 19505 Biscayne Blvd., 3rd Floor, Suite 2350, Aventura, FL 33180
Products
Multifunctional Antibody Platform
A platform for designing and developing multifunctional antibodies targeting cancer and autoimmune diseases.
GPC3-targeted NK Engager Bispecific Antibody
A bispecific antibody designed to engage natural killer cells targeting GPC3-expressing hepatocellular carcinoma cells.
Fertility Treatment Services (INVOcell)
Fertility treatment services utilizing the INVOcell device for intravaginal embryo incubation.
Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)
A gene therapy program targeting LHON, a mitochondrial genetic disorder causing vision loss.
Multifunctional Antibody Platform
A platform for designing and developing multifunctional antibodies targeting cancer and autoimmune diseases.
GPC3-targeted NK Engager Bispecific Antibody
A bispecific antibody designed to engage natural killer cells targeting GPC3-expressing hepatocellular carcinoma cells.
Fertility Treatment Services (INVOcell)
Fertility treatment services utilizing the INVOcell device for intravaginal embryo incubation.
Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)
A gene therapy program targeting LHON, a mitochondrial genetic disorder causing vision loss.
Expertise Areas
- Fertility
- Oncology
- Web accessibility compliance
Key Technologies
- Web accessibility standards (WCAG 2.1 Level A/AA)
News & Updates
Press release announcing the strategic decision to separate the company's fertility and oncology businesses into distinct operations (linked from the company homepage).
Press release announcing the strategic decision to separate the company's fertility and oncology businesses into distinct operations (linked from the company homepage).